This website is intended for journalists outside the US/UK, who are interested in media information from Boehringer Ingelheim.

Latest Press Releases

08.07.2014

Boehringer Ingelheim’s volasertib showed in a Phase II study an improvement in overall survival in older AML patients

-

For media outside of the US/UK only

07.07.2014

Judit Makara wins Boehringer Ingelheim’s FENS Award 2014 for Exceptional Research in Neuroscience

-

For Non-US, Non-UK Media Only

02.07.2014

COPD: Boehringer Ingelheim submits applications in Europe for tiotropium + olodaterol Respimat® fixed-dose combination in COPD

-

For media outside UK, U.S. and Canada

30.06.2014

U.S. FDA grants Breakthrough Therapy Designation to Pradaxa® (dabigatran etexilate) specific investigational antidote

-

For media outside of the U.S., the UK & Canada only

27.06.2014

CHMP Recommends Lilly and Boehringer Ingelheim’s New Insulin Glargine Product for Approval in the European Union

-

For Non-U.S. and Non-U.K. Media

20.06.2014

Boehringer Ingelheim Statement on Hepatitis C drug development

-

For media outside of the US, the UK only

20.06.2014

New Pradaxa® clinical study to explore practical management of patients with atrial fibrillation undergoing ablation

-

For media outside of the U.S., the UK & Canada only

16.06.2014

Type 2 Diabetes: Jardiance® (empagliflozin) as an add-on therapy significantly reduced blood glucose and body weight in two newly presented Phase III trials

-

For Non-U.S. and Non-U.K. Media

16.06.2014

MEDIA ALERT


New survey in five European countries reveals urgent need to improve education about Acute Myeloid Leukaemia

-

For media outside of the US/UK only

Top Stories

 

  •  

    ASCO 2014: Giotrif® (afatinib) analysis presented

  •  

    ASCO 2014: New data presented

    Events and Initiatives

    ASCO 2014

    30 May - 3 June 2014
    ASCO 2014: Boehringer Ingelheim to present latest oncology research, including overall survival results for Giotrif® (afatinib) in advanced NSCLC

    Education Hub

     

    VIDEO

    Professor James Chih-Hsin Yang
    Lux-Lung 3 and Lux-Lung 6 :
    study design

     

    INFOGRAPHIC

    Nintedanib* Lume-Lung
    1 Clinical Trials

    INFOGRAPHIC

    Afatinib* Lux-Lung 3 & 6
    Clinical Trials

    Tweets from @Boehringer